Testing a new blood marker for early detection of Parkinson's disease

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Parkinson's disease, either newly diagnosed and not yet on dopamine treatment, or advanced and on dopamine treatment. It also looks for adults with multiple system atrophy.

Age

18 years and older

Sex

All sexes can join.

Disease stage

Newly diagnosed Parkinson's disease without dopamine treatment, advanced Parkinson's disease (more than 5 years) with dopamine treatment, or multiple system atrophy.

Earlier treatment

Newly diagnosed patients must not be on dopamine treatment. Advanced patients must be on dopamine treatment.

Main reasons for not taking part

• Deep brain stimulation
• Other neurodegenerative diseases
• People protected by French law (pregnant or breastfeeding women, prisoners, ...)

The registry criteria, word for word

What the trial wants to find out

The investigators have recently discovered a metabolic biomarker which predicts Parkinson's disease (PD) at the early stages in patients and in animal models. The aim of BIOPARK is to investigate how the biomarker evolves in advanced PD stage, when diagnosis confirmation is higher, an in de novo PD patients who come from a different geographical area than those of the publication (since it is known that the metabolome is largely influenced by lifestyle). They will also evaluate if the biomarker is able to distinguish patients with a parkinsonian syndrome often confused with parkinson's disease, i.e. Multiple System Atrophy (MSA).

The 3 groups in the trial

• Parkinson's Disease, de novo

  patients with de novo PD, without dopaminergic treatment

• Parkinson's Disease, advanced stage

  PD patients with diagnosis \>5years, with dopaminergic treatment and motor fluctuations.

• Multiple system atrophy

  patients with multiple system atrophy